Key facts
- It has raised $1.7M; the latest was Seed Round ($530K) in Nov 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for A-Synaptic
- ·The full record, as it builds
Funding rounds
No funding rounds for A-Synaptic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About A-Synaptic
Developer of transdermal delivery technology intended to create prescriptive drugs addressing orphan drug status medical conditions. The company specializes in combining cannabinoids and herbal extracts in a validated, transdermal, transmucosal, and edible technology that can be applied through a single-dose system, enabling patients to overcome the hydrophilic and lipophilic structures in the skin.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2018
- Website
- asynaptic.com/
- Ownership
- Privately Held (backing)
A-Synaptic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A-Synaptic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A-Synaptic in its N-PORT filings yet. We sweep new filings monthly.